Literature DB >> 29875123

Establishing the role of PLVAP in protein-losing enteropathy: a homozygous missense variant leads to an attenuated phenotype.

Alina Kurolap1,2, Orly Eshach-Adiv2,3, Claudia Gonzaga-Jauregui4, Katya Dolnikov5, Gidon Berger2,5, Hagit N Baris1,2, Adi Mory1, Tamar Paperna1, Tova Hershkovitz1, John D Overton4, Marielle Kaplan2,6, Fabian Glaser7, Yaniv Zohar8, Alan R Shuldiner4.   

Abstract

BACKGROUND: Intestinal integrity is essential for proper nutrient absorption and tissue homeostasis, with damage leading to enteric protein loss, that is, protein-losing enteropathy (PLE). Recently, homozygous nonsense variants in the plasmalemma vesicle-associated protein gene (PLVAP) were reported in two patients with severe congenital PLE. PLVAP is the building block of endothelial cell (EC) fenestral diaphragms; its importance in barrier function is supported by mouse models of Plvap deficiency.
OBJECTIVE: To genetically diagnose two first-degree cousins once removed, who presented with PLE at ages 22 and 2.5 years.
METHODS: Family-based whole exome sequencing was performed based on an autosomal recessive inheritance model. In silico analyses were used to predict variant impact on protein structure and function.
RESULTS: We identified a rare homozygous variant (NM_031310.2:c.101T>C;p.Leu34Pro) in PLVAP, which co-segregated with the disease. Leu34 is predicted to be located in a highly conserved, hydrophobic, α-helical region within the protein's transmembrane domain, suggesting Leu34Pro is likely to disrupt protein function and/or structure. Electron microscopy and PLVAP immunohistochemistry demonstrated apparently normal diaphragm morphology, predicted to be functionally affected.
CONCLUSIONS: Biallelic missense variants in PLVAP can cause an attenuated form of the PLE and hypertriglyceridaemia syndrome. Our findings support the role of PLVAP in the pathophysiology of PLE, expand the phenotypic and mutation spectrums and underscore PLVAP's importance in EC barrier function in the gut. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  PLVAP; hypertriglyceridemia; plasmalemma vesicle-associated protein; protein-losing enteropathy

Mesh:

Substances:

Year:  2018        PMID: 29875123     DOI: 10.1136/jmedgenet-2018-105299

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  3 in total

1.  Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia.

Authors:  Michael Maes; Sunee Sirivichayakul; Buranee Kanchanatawan; Aristo Vodjani
Journal:  Neurotox Res       Date:  2019-05-10       Impact factor: 3.911

2.  Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner.

Authors:  B JoNell Hamilton; Dan Tse; Radu V Stan
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

3.  Enhanced Collagen Deposition in the Duodenum of Patients with Hyaline Fibromatosis Syndrome and Protein Losing Enteropathy.

Authors:  Jorik M van Rijn; Lael Werner; Yusuf Aydemir; Joey M A Spronck; Ben Pode-Shakked; Marliek van Hoesel; Elee Shimshoni; Sylvie Polak-Charcon; Liron Talmi; Makbule Eren; Batia Weiss; Roderick H J Houwen; Iris Barshack; Raz Somech; Edward E S Nieuwenhuis; Irit Sagi; Annick Raas-Rothschild; Sabine Middendorp; Dror S Shouval
Journal:  Int J Mol Sci       Date:  2020-11-02       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.